Tcr2 Therapeutics (NASDAQ:TCRR) Issues Earnings Results, Misses Estimates By $0.03 EPS

Tcr2 Therapeutics (NASDAQ:TCRR) announced its earnings results on Tuesday. The company reported ($0.58) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.03), Fidelity Earnings reports.

NASDAQ:TCRR traded up $0.26 on Friday, hitting $15.13. 302 shares of the company’s stock were exchanged, compared to its average volume of 79,450. The firm has a 50-day moving average price of $14.65 and a 200-day moving average price of $15.27. Tcr2 Therapeutics has a 52 week low of $10.04 and a 52 week high of $25.47. The company has a market cap of $357.10 million and a P/E ratio of -0.15.

In other Tcr2 Therapeutics news, major shareholder Morana Jovan-Embiricos sold 416,321 shares of the business’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $17.92, for a total transaction of $7,460,472.32. Insiders have sold a total of 484,313 shares of company stock worth $8,609,469 over the last three months. Insiders own 39.07% of the company’s stock.

A number of equities analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $19.00 target price on shares of Tcr2 Therapeutics in a research note on Wednesday. Zacks Investment Research raised shares of Tcr2 Therapeutics from a “hold” rating to a “buy” rating and set a $17.00 target price for the company in a research note on Thursday. Finally, ValuEngine lowered shares of Tcr2 Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, September 27th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Tcr2 Therapeutics presently has a consensus rating of “Buy” and an average price target of $25.00.

About Tcr2 Therapeutics

TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.

Further Reading: What are the components of an earnings report?

Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with's FREE daily email newsletter.